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ABSTRACT
Colorectal cancer (CRC) remains one of the leading causes of cancer related
deaths in the United States. Currently, there are limited therapeutic options for
patients suffering from CRC, none of which focus on the cell signaling mechanisms
controlled by the popular kinase family, cyclin dependent kinases (CDKs). Here we
evaluate a Pfizer developed compound, CP668863, that inhibits cyclin-dependent
kinase 5 (CDK5) in neurodegenerative disorders. CDK5 has been implicated in a
number of cancers, most recently as an oncogene in colorectal cancers. Our lab
synthesized and characterized CP668863 – now called 20-223. In our established
colorectal cancer xenograft model, 20-223 reduced tumor growth and tumor weight
indicating its value as a potential anti-CRC agent. We subjected 20-223 to a series
of cell-free and cell-based studies to understand the mechanism of its anti-tumor
effects. In our hands, in vitro 20-223 is most potent against CDK2 and CDK5. The
clinically used CDK inhibitor AT7519 and 20-223 share the aminopyrazole core and we
used it to benchmark the 20-223 potency. In CDK5 and CDK2 kinase assays, 20-223
was ~3.5-fold and ~65.3-fold more potent than known clinically used CDK inhibitor,
AT7519, respectively. Cell-based studies examining phosphorylation of downstream
substrates revealed 20-223 inhibits the kinase activity of CDK5 and CDK2 in multiple
CRC cell lines. Consistent with CDK5 inhibition, 20-223 inhibited migration of CRC
cells in a wound-healing assay. Profiling a panel of CRC cell lines for growth inhibitory
effects showed that 20-223 has nanomolar potency across multiple CRC cell lines and
was on an average >2-fold more potent than AT7519. Cell cycle analyses in CRC cells
revealed that 20-223 phenocopied the effects associated with AT7519. Collectively,
these findings suggest that 20-223 exerts anti-tumor effects against CRC by targeting
CDK 2/5 and inducing cell cycle arrest. Our studies also indicate that 20-223 is a
suitable lead compound for colorectal cancer therapy.
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(CP668863 a.k.a 20-223), that was developed to treat
neurodegenerative disorders [23]. Preliminary xenograft
studies showed 20-223 reduced tumor growth and tumor
weight in vivo indicating that 20-223 is a suitable lead
compound for CRC therapy. We subjected 20-223 and
AT7519 to a series of cell-free and cell-based assays to
understand the mechanistic basis of the observed 20-223
anti-tumor effects. Docking studies suggested both 20223 and AT7519 are ATP competitive inhibitors. The two
aminopyrazole analogs were compared head-to-head in
cell free kinase assays which demonstrated 20-223 was
more potent than AT7519. Contrary to a previous report,
we found 20-223 was equipotent against CDK2 and
CDK5 compared to other members of the CDK family.
Examination of downstream substrate phosphorylation
showed 20-223 inhibited the kinase activity of CDK2 and
CDK5. Migration studies utilizing a wound-healing assay
showed that 20-223 decreased CRC cell migration. 20223 was a nanomolar inhibitor of cell growth in a panel of
CRC cell lines and was more potent than AT7519. Finally,
20-223 phenocopied cell cycle effects associated with
AT7519. Together, our studies suggest 20-223 is a CDK
2/5 inhibitor, an effective anti-CRC agent and suitable lead
for pre-clinical development.

INTRODUCTION
Colorectal cancer (CRC) continues to be a major
health concern in the United States where it is currently
the fourth most commonly diagnosed malignancy and the
second leading cause of cancer related deaths [1]. Despite
numerous attempts at developing promising therapies for
CRC, few have successfully improved patient outcome.
Cyclin-dependent kinases (CDKs) have been
extensively studied and characterized for their roles in
cancer. There are 20 members of the CDK family, all
of which have been linked to cancer. CDKs are often
categorized into two major groups, those that contribute
to tumorigenesis through cell cycle control and those
that regulate transcription [2–4]. One peculiar member of
the CDK family that does not regulate transcription and
only recently has been shown to contribute to cell cycle
progression, is CDK5. Uniquely, CDK5 is not activated in
typical CDK fashion i.e., through binding of cyclins, but
instead is activated by regulatory proteins p35 and p39
[5]. CDK5 is best known for its role in the central nervous
system where it regulates development, axon elongation,
synaptogenesis and neuronal migration. Recently, reports
have identified CDK5 as a key player in non-neuronal
functions including apoptosis, senescence, angiogenesis,
insulin secretion, wound healing, and adhesion/migration
[6]. These functions associated with CDK5 are believed
to contribute to its role in tumorigenesis. CDK5 has been
previously implicated in a number of cancers, including
those of the pancreas [7, 8], thyroid [9, 10], prostate [11,
12], breast [13], lung [14], liver [15], and most recently as
a tumor promoter in CRC [16].
CDKs have received a lot of attention as potential
targets for cancer therapy. The traditional approach to
targeting CDKs, which still remains popular, is through
the use of ATP-competitive inhibitors that bind within
the catalytic sites of CDKs and outcompete the binding
of ATP. The earliest CDK inhibitors were pan-CDK
inhibitors that often targeted most, if not all the members
of the family. While they showed promise in targeting
CDKs, they often required high doses which resulted in
off-target effects and significant toxicity in preclinical
animal trials [17]. To address these issues, substantial
efforts have been made to improve upon the potency of
CDK inhibitors. While CDK inhibitors are currently being
used to treat a variety of malignancies, few are currently
being tested in CRC [18].
ATP competitive inhibitors typically form hydrogen
bonds with the residues in the hinge region of the kinase.
Aminopyrazole is a privileged scaffold that forms a
network of hydrogen bonds between 3 nitrogen atoms of
the scaffold and the hinge region of the kinase [19, 20].
AT7519, a well-characterized pan-CDK inhibitor built on
a 4-aminopyrazole core has shown promise in pre-clinical
and clinical studies [21–23].
Herein, we describe our findings with a
3-aminopyrazole analog previously reported by Pfizer
www.impactjournals.com/oncotarget

RESULTS
TCGA analyses reveals CDK5 is upregulated
in primary colorectal tumors as a result of
increased copy number
With increasing evidence suggesting a role for
CDK5 in a variety of malignancies, we turned to The
Cancer Genome Atlas (TCGA – http://cancergenome.nih.
gov/) database to gain insight into CDK5 expression in
patient populations. We found the colorectal cancer cohort
in TCGA online database consisted of 50 samples of
normal mucosa and 347 primary colorectal tumor samples.
The mRNA profiles of these samples were examined for
CDK5 expression. As seen in Supplementary Figure 1A,
CDK5 mRNA levels were significantly higher in primary
tumor compared to normal colon. Additional analyses
that compared normal tissue with corresponding primary
tumor revealed that of the 31 patients examined, all but
two showed a significant increase in CDK5 levels in
primary tumors when compared to normal colon tissue
(Supplementary Figure 1B). Next we examined the CDK5
copy number to determine whether increased CDK5
levels correspond to increased copy number. Of the 616
sequenced CRC samples, few exhibited homozygous
deletion or heterozygous loss of CDK5 (0.3% and 1.9%
respectively). Interestingly, 46.0% of individuals were
diploid for CDK5 while 51.9% of individuals had a copy
number gain for CDK5 (Supplementary Figure 1C).
Additionally, we found that across all four groups, there
is a significant linear trend. As copy number of CDK5
increases there is a corresponding increase in mRNA
5217
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expression (Supplementary Figure 1D) thus suggesting
that copy number is a contributing factor to increased
mRNA expression that we observed in CRC. Next, we
investigated whether CDK5 mutation could possibly be
contributing to its activity in CRC so we examined the
mutational frequency of CDK5 in all TCGA cancers. We
found that CDK5 is rarely mutated across cancers and
more importantly is not mutated in CRC (Supplementary
Figure 1E). Collectively, this data suggests that CDK5
activity is a result of increased expression that results
from an increase in copy number. Furthermore, it is the
increase in CDK5 expression, not a mutation, which is
likely responsible for its contributions to CRC. These
data are consistent with a recent report implicating
CDK5 as a tumor promoter in CRC and thus warrants
the investigation into inhibition of CDK5 as a potential
therapeutic option for CRC [16].

greater than average tumor volume in the 20-223-treated
group (~429mm3 vs. ~197mm3). The tumor volumes
of DMSO-treated animals continued to grow rapidly,
while the tumor progression in 20-223-treated animals
was slower (Figure 1C). At the conclusion of the study,
tumors from the DMSO treated mice were significantly
larger (~3-fold: 1138 mm3 vs. 386 mm3) than the tumors
from the 20-223-treated mice. We also found a decrease in
GFP fluorescence in 20-223-treated tumors compared to
DMSO-treated tumors, which is consistent with the tumor
volume trends (Figure 1D). The average tumor weights
from DMSO-treated mice were also ~2-fold greater than
tumors from 20-223-treated mice (0.7g vs. 0.3g) (Figure
1E). Of note, 20-223 treated animals did not exhibit any
overt signs of toxicity, as there was no change in animal
weight or behavior.
To confirm inhibition of CDK5 in vivo, we
performed western blot analyses on the tumor lysates
with tumors from three representative animals from each
treatment group. 20-223-treated tumors showed a decrease
in the pFAK levels, a phosphorylation site specific to
CDK5 [27], (Supplementary Figures 2C) suggesting
inhibition of CDK5 in vivo. In summary, these studies
suggest that 20-223 treatment results in anti-tumor activity
in a CRC xenograft model.

20-223 shows anti-tumor activity in human CRC
xenograft tumors
CP668863, a substituted 3-aminopyrazole analog,
was first reported by Pfizer as an ATP-competitive
CDK5 inhibitor that was explored for the treatment
of neurodegenerative disorders [24]. With increasing
evidence that CDK5 activity contributes to CRC
tumorigenesis, we synthesized CP668863 (a.k.a 20-223)
to screen for its efficacy against CRC. We utilized our well
established CRC xenograft model [25] to determine the
effects of 20-223 in vivo. GEO cells were chosen because
they form primary tumors 100% of the time and frequently
exhibit metastatic spread (approximately 53%) in animal
models [26]. As our xenograft model uses GEO cells,
we performed an initial growth inhibition study to show
efficacy of 20-223 in this cell line. We found 20-223 to
have an IC50 value of 79nM in GEO cells (Figure 1A). We
used a GEO cell line in which GFP is stably expressed, for
our xenograft model. GEO-GFP cells were subcutaneously
injected into the flank of athymic nude mice and allowed
tumors to grow to ~100 mm3. Animals with tumors
were then randomly divided into two treatment groups
(I) DMSO or (II) 8mg/kg 20-223. In preliminary PK
studies, mice were dosed with 8mg/kg of 20-223. The
plasma concentration was greater than 79nM for 24 hours
as determined by LC-MS (Supplementary Figure 2A).
Subcutaneous injections were given in the shoulder area
of each mouse daily for the first week and every other
day for the following two weeks (Figure 1B). The mice
were weighed and tumor volumes were measured every
other day. At the end of the three-week treatment period
the mice were euthanized and the tumors excised, weighed
and imaged (Supplementary Figure 2B).
Average changes in tumor volume for both
treatment groups are summarized in Figure 1C. At the
end of the first week of treatment, average tumor volume
in the DMSO-treated group was approximately 2-fold
www.impactjournals.com/oncotarget

20-223 is an ATP-competitive inhibitor
Our in vivo data suggests 20-223 may be a
promising therapeutic agent for CRC, therefore we began
to evaluate and characterize it in cell-free and cell-based
studies. We started with docking studies that compared 20223 to another known CDK inhibitor, AT7519, which is
currently in clinical trials and shares the aminopyrazole
core structure with 20-223 [21, 23].
X-ray crystallographic studies of reported
aminopyrazole analogs and CDKs showed that they
occupy the ATP binding site in the CDKs [18, 19]. Since
there is no co-crystal structure of 20-223, we docked
20-223 into CDK5 using Autodock Vina to explore its
binding mode. Our docking studies revealed that 20223 indeed occupied the ATP binding site of CDK5 and
the three nitrogen atoms of the 3-aminopyrazole core
are involved in a donor-acceptor-donor hydrogen bond
triad with Glu81 and Cys83 of the hinge region. The
cyclobutyl ring occupied a narrow hydrophobic pocket
formed by Phe80, Leu55 and Val64 and the naphthalene
ring of 20-223 is directed towards the solvent-accessible
region of the kinase (Figure 2A). Since CDK2 and CDK5
share sequence homology of ~60% (5), we overlaid
the co-crystal structure of an aminopyrazole analog
PNU-181227-CDK2 with our docked 20-223-CDK5
and observed similar binding mode (Figure 2B). X-ray
crystallographic studies demonstrated AT7519 to be an
ATP-competitive CDK inhibitor [21]. Overlay of AT7519
complexed with CDK2 and docked 20-223-CDK5 showed
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similar mode of binding with similar hydrogen bonding
interactions anchoring the molecules to the hinge region
(Figure 2C). The chemical structures of all three of these
compounds are compared in Figure 2D.

Cell free kinase assays reveal 20-223 is a CDK
2/5 inhibitor
In order to determine the selectivity profile of
20-223 for various CDKs we conducted a single dose

Figure 1: 20-223 exhibits anti-tumor activity in a colorectal cancer xenograft model. (A) Growth Inhibition of GEO cells
after 72 hour treatment with 20-223. (B) Schematic representation of CRC xenograft model using GEO-GFP cells. (C) Average tumor
volume comparison of DMSO and 20-223 treated tumors throughout the study. (D) Average GFP Flurorescence in DMSO and 20-223
treated tumors. (E) Average tumor weight of DMSO and 20-223 treated tumors.
www.impactjournals.com/oncotarget
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kinase screen with a panel of CDKs. Members of the
CDK family bound to their respective activators were
LQFXEDWHG ZLWK ȝ0 RI  DQG ȝ0 $73 7KH
percentage remaining enzymatic activity was determined
for each of the examined CDKs after inhibition by 20-223
(Figure 2E). Incubation with 20-223 markedly inhibited
the enzymatic activity CDK2 and CDK5 with only 0.26%
and 0.39% enzymatic activity remaining. 20-223 was
less effective against the enzymatic activity of CDK1,
CDK4, CDK6, CDK7, and CDK9. These results show
that 20-223 is most effective against CDK2 and CDK5
in a cell-free system. To determine IC50 values of 20-223
against CDK2/5 we performed a dose-response study.
CDK2/CyclinE and CDK5/p35 were incubated with 20223 at various concentrations and IC50 values of 6.0nM
for CDK2 and 8.8nM for CDK5 were derived from curve
fitting the data (Figure 2F). Similar studies were also
carried out with AT7519 and IC50 values of 392nM for
CDK2 and 32.8nM for CDK5 were obtained. Results from
the dose-response study show that 20-223 is equipotent
against CDK2 and CDK5 in a cell-free system and is more
potent than comparable CDK inhibitor, AT7519.

substrate phosphorylation, three CRC cell lines were
chosen: GEO, HCT116 and HT29. CRC cells were
LQFXEDWHGZLWK'062RUYDULRXVFRQFHQWUDWLRQV ȝ0
– 2-fold dilutions, 7 doses) of 20-223 for 6 hours prior
to western blot analyses. In the dose response study, 20223 did not affect the total levels of CDK2 or CDK5
(Figure 3B), nor did it affect the levels of total FAK or
total RB (Supplementary Figure 3). As expected, 20-223
induced a dose-dependent decrease in pRB (S807/811)
and pFAK (S732) levels in each of the three CRC cell
lines (Figure 3B). Quantification of phosphorylated RB
and FAK levels was performed to reveal the effect of the
inhibitor on CDK2 and CDK5 kinase activity, respectively.
As the concentration of 20-223 increased, there was a
corresponding increase in % kinase inhibition for CDK2
and CDK5 (Figure 3C). This pattern was consistent
for each of the three cell lines. Quantification was also
used to assess the fold selectivity of 20-223 in each of
the three cell lines. Figure 3D summarizes the cell-based
IC50 values for each cell line. 20-223 was ~10 fold more
VHOHFWLYHIRU&'.RYHU&'.LQ*(2FHOOV ȝ0
YVȝ0 DQGaIROGPRUHVHOHFWLYHIRU&'.RYHU
&'.LQ+&7FHOOV ȝ0YVȝ0 +RZHYHU
in HT29 cells, 20-223 was equally potent against CDK5
DQG&'. ȝ0YVȝ0 :KLOHWKHJHQHUDWHG,&50
values are based on a qualitative observation, these results
demonstrated that 20-223 effectively blocks the kinase
activity of CDK2 and CDK5 in multiple CRC cell lines.

CDK2 and CDK5 expression and
phosphorylation activity in a panel of human
CRC cell lines
Having determined that 20-223 targets CDK2 and
CDK5, we next examined the basal levels of these kinases
in a cohort of colorectal cancer cell lines which includes
seven CRC cell lines and one normal human colon
epithelial cell line (HCEC). All the cell lines expressed
CDK2 and CDK5, albeit at different levels. HCEC cells
also expressed CDK2 and CDK5 but at much lower
levels than many of the CRC cell lines (Figure 3A). This
observation is consistent with the TCGA data.
As a measure of CDK2 and CDK5 activity we
examined basal phosphorylation levels of substrates
specific to CDK2 and CDK5. Phosphorylation levels
of RB (S807/811) were used as a read-out for CDK2
kinase activity. While CDK4 has also been shown to
phosphorylate RB at S807/811 [28, 29], our kinase profile
screen showed 20-223 targets CDK2/5 more effectively
than CDK4/6. Phosphorylation levels of FAK (S732) were
used as a read out for CDK5 kinase activity [27] [28]. We
observed differential phosphorylation of RB (S807/811)
and FAK (S732) indicating both CDK2 and CDK5 are
active in each of the cell lines (Figure 3A).

20-223 reduces migration of CRC cells
Since 20-223 effectively inhibits CDK2 and CDK5,
both of which have previously been shown to regulate cell
motility [27, 30], we next examined its ability to disrupt
CRC cell migration. Wound-healing scratch assays are
routinely used to assess the effect of small molecule
inhibitors on the ability of cells to migrate [31]. EGFstimulated wound healing has previously been shown to
enhance migration of cells; therefore, we used this ligand
to stimulate CRC cells for migration [32]. We checked
protein levels of CDK2/5 and their substrates after EGF
stimulation (100ng/mL) to ensure that treatment with
EGF would not affect their basal levels or activity. Upon
treatment with EGF, no changes in the levels of CDK2/5
or pRB/pFAK were observed, indicating that EGF is
not affecting the expression or activity of these kinases
(Supplementary Figure 4A). HCT116 cells were used
to model cell migration because they have been used
previously in wound-healing scratch assays [35]. To
assess the ability of 20-223 to inhibit migration, HCT116
cells were stimulated with EGF and treated with DMSO
RU ȝ0 RI  /LYH FHOO LPDJLQJ ZDV XWLOL]HG WR
monitor cell motility through the 24 hour incubation period
at 15 min intervals (Supplementary Figure 4B & 4C). Still
images and zoomed in regions of the images emphasize
the ability of 20-223 to inhibit cell migration (Figure 4A).

20-223 disrupts CDK2 and CDK5 kinase activity
in cell-based studies
Since 20-223 was shown to most potently inhibit
CDK2 and CDK5 in a cell-free system, we next explored
the ability of 20-223 to target CDK2 and CDK5 in a
cellular setting. To characterize the effects of 20-223 on
www.impactjournals.com/oncotarget
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Figure 2: Structural and cell free analyses of 20-223 and AT7519. (A) Docking of 20-223 into CDK5 using AutoDock Vina
software. (B) Overlay of 20-223 and PNU181227 in the hinge region of CDK5. (C) Overlay of 20-223 and AT7519 in the ATP binding
pocket. (D) Chemical structures of 20-223, PNU-181227, and AT7519. (E) % of remaining enzymatic activity of a panel of CDKs after
LQFXEDWLRQZLWKȝ0DQGȝ0$73(F) IC50 values (nM) of CDK2 and CDK5 after incubation with 20-223 or AT7519 in cell
free dose-escalation study.
www.impactjournals.com/oncotarget
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Figure 3: 20-223 inhibits the kinase activity of CDK5 and CDK2 in vitro. (A) Baseline expression of CDK2 and pRB (S807/811)
(left), CDK5 and pFAK (S732) (right), in untreated CRC cells. (B) Representative western blots of target substrate pRB and pFAK
phosphorylation levels in GEO (left), HCT116 (middle) and HT29 (right) cell lines after 6 hour incubation with 20-223. (C) Representative
quantification of % inhibition of CDK2 and CDK5 kinase activity (based on substrate phosphorylation levels) in GEO cells found in Figure
3B. (D) Cell-based IC50 values generated from phosphorylation levels in Figure3B of CDK2 and CDK5 in three CRC cell lines.

www.impactjournals.com/oncotarget
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HCT116 cells treated with DMSO had greater ability
to migrate into the open wound areas compared to cells
treated with 20-223. While cells treated with DMSO were
able to close approximately 40% of the wound area, cells
treated with 20-223 only closed approximately 10% of the
wound (Figure 4B). To confirm that the reduced migration
was a result of CDK2/5 inhibition, corresponding western
blots were performed under the same conditions as the
migration experiment and pFAK and pRB levels were
GHWHUPLQHGDIWHUWUHDWPHQWZLWK(*)DQGȝ0RI
223. Although treatment with 20-223 effectively reduced
the phosphorylation levels of both FAK (S732) and RB
(S807/811) (Figure 4C), the effects were more pronounced
on the FAK phosphorylation over RB phosphorylation.
Collectively, these results suggest that inhibition of
CDK2/5 by 20-223 disrupts CRC cell migration.

Reduced CRC cell growth and tumor growth
induced by 20-223 is probably not due to the
induction of apoptosis
To determine if induction of apoptosis was
responsible for potent CRC cell growth inhibition, we
examined the effect of 20-223 on Poly(ADP-ribose)
polymerase (PARP) cleavage. PARP cleavage is one of the
hallmarks of cell death and is widely used as a read-out
of apoptosis in cancer research. To determine the effect
of 20-223 on cell death, we evaluated the panel of CRC
cells treated with 20-223 for PARP cleavage. CRC cell
lines treated with 20-223 for 24 hours all exhibited PARP
cleavage (Supplementary Figure 5A). Next, we performed
a dose-response and a time course study in GEO cells and
IRXQGWKDWȝ0FRQFHQWUDWLRQVRIDQGORQJH[SRVXUH
were required to induce apoptosis (Supplementary Figure
5B and 5C). This suggests that the reduced tumor growth
observed in the mouse model is not due to induction of
apoptosis.

20-223 reduces cell growth in a panel of human
CRC cell lines
Since 20-223 effectively targets CDK2 and CDK5,
we next examined its effect on cell growth. We subjected
a panel of CRC cell lines to treatment with three CDK
inhibitors (20-223, AT7519 or Roscovitine). Roscovitine,
which contains a purine core, was one of the first CDK
inhibitors to enter clinical trials. CRC cells were treated
with 20-223, AT7519 and Roscovitine at four-fold
GLOXWLRQVVWDUWLQJDWȝ0 DQG$7 RUȝ0
(Roscovitine). Among the three inhibitors, 20-223 had
lower IC50 values when compared to the clinically used
CDK inhibitors, AT7519 and Roscovitine (Figure 5A).
Among the CRC cell lines, SW620, GEO and FET cells
were the most sensitive to 20-223, whereas HCT116
and HT29 were more responsive to AT7519 treatment
as evident by lower IC50 values. It is important to note
that a ~10-fold higher dose of Roscovitine was required
to observe similar growth inhibitory effects. Average IC50
values were calculated across cell lines to determine the
overall efficacy for each compound (Figure 5B). 20-223
had an overall average IC50 value of 362nM across seven
cell lines, while AT7519 and Roscovitine had overall
average IC50 values of 799nM and 11481nM respectively,
thus suggesting 20-223 is a more potent inhibitor of
cell growth compared to the clinical compounds. CRC
mutational profiles [33–39] (Figure 5C) were examined
to determine if the presence of any particular mutations
made any cell line more or less responsive to treatment
with 20-223. We did not find any obvious correlation
between IC50 values and the mutational profile. Based
RQWKHVHILQGLQJVZHFRQFOXGHWKDWLVDVXEȝ0
inhibitor of CRC cell growth. Specifically, these data show
that 20-223 is ~2.2 fold and ~31.7 fold more potent than
AT7519 and Roscovitine, respectively. Therefore, 20-223
is comparable or marginally better than the CDK inhibitors
advanced to the clinics.

www.impactjournals.com/oncotarget

Reduced CRC cell growth and tumor growth in
mice is probably due to the induction of cell cycle
arrest by 20-223
The CDK family has been extensively studied
for its regulation of all phases of the cell cycle. This
kinase family is essential for normal cells to proliferate
and divide. CDK2 has been shown numerous times to
be required for progression from G1 and S phase of the
cell cycle [40]. The role of CDK5 in cell cycle is less
understood however, recent reports suggest it regulates the
cell cycle through mitotic control and dysregulation of cell
cycle inhibitors, p21CIP1 and p27 [41–43]. Having shown
that 20-223 effectively targets CDK2 and CDK5 and also
decreases cell growth, we sought out to understand how it
may alter cell cycle progression. GEO and HCT116 cells
were treated with either DMSO, AT7519 or 20-223 for
24 and 48 hours and then analyzed for DNA content by
flow cytometry. The results from the above experiment
are summarized in Figure 6A. 20-223 and AT7519 both
effectively arrested the CRC cells in either the G2 or S
phase of the cell cycle. GEO cells treated with either
20-223 or AT7519 arrested in G2 phase of the cell
cycle (Figure 6B). This is consistent with the previous
findings that CDK2 regulates the G2/M checkpoint in
the absence of functional p53 [44]. Profiling the GEO
cell line indicates that GEO cells carry a p53 mutation,
therefore the G2/M arrest seen in GEO cells may be due
to CDK2 inhibition. Alternatively, the G2 arrest could also
be attributed to CDK1 inhibition as it was the third CDK
inhibited in our profiling. HCT116 cells treated with either
20-223 or AT7519 resulted in S-phase arrest at the 24 and
48 hour time point. Figure 6B shows representative traces
from the cell cycle analyses. The data clearly shows that
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Figure 4: 20-223 disrupts migration of CRC cells. (A) Wound gap images taken during the 24 hour incubation of HCT116 cells

ZLWK'062RUȝ0DQGKRXULPDJHVZHUHIXUWKHUHYDOXDWHGE\RXWOLQLQJWKHZRXQGDUHD UHGOLQHV DQG]RRPLQJLQRQWKH
wound boundaries (yellow box). (B)4XDQWLILFDWLRQRIZRXQGFORVXUHDIWHUWUHDWPHQWRI+&7FHOOVZLWK'062RIȝ0(C)
:HVWHUQEORWDQDO\VHVDWDQGKRXUVDIWHUVWLPXODWLRQZLWK(*)DQGWUHDWPHQWZLWKHLWKHU'062RUȝ0
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20-223 mimics the effects observed with AT7519. This
data suggests that the observed CRC cell growth inhibition
and the tumor growth in mice induced by 20-223 were due
to cell cycle arrest.

DISCUSSION
There is a need for targeted agents with defined
mechanism of action for CRC therapy. Recent studies
have validated CDK5 as a tumor promoter and designated

Figure 5: 20-223 potently inhibits cell growth in a panel of CRC cell lines. (A) IC50 values from growth inhibition studies after
CRC cells were treated with 20-223, AT7519 or Roscovitine for 72 hours. (B) Average IC50 values across all seven CRC cell lines after
treatment with 20-223, AT7519, or Roscovitine (P < 0.001). (C) Panel containing the seven CRC cell lines used in this study and mutational
status of important regulatory genes.
www.impactjournals.com/oncotarget
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it as a therapeutic target for CRC therapy. In the present
study, we evaluated 20-223 (CP668863), a previously
identified CDK5 inhibitor, for its potential as an anti-CRC
agent. In a proof of concept study, we used an established
CRC xenograft model to show that 20-223 effectively

slowed tumor progression. Tumors in mice treated with
20-223 had reduced tumor volumes and tumor weights
compared to vehicle-treated mice. Moreover, we observed
lower levels of phosphorylated FAK, a well-characterized
target of CDK5, in 20-223 treated tumors as compared to

Figure 6: 20-223 treatment in CRC cells results in cell cycle arrest in vitro. (A) % of cells in each phase of the cell cycle
after treatment with DMSO, AT7519, or 20-223 for 24 (top) and 48 (bottom) hours in GEO (left) and HCT116 (right) cells. (B) Traces
representative of cell cycle analysis in GEO cells after treatment with DMSO, AT7519, or 20-223 after 24 (left) or 48 (right) hours.
www.impactjournals.com/oncotarget
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vehicle-treated tumors. These results are consistent with
the studies reported with the neurodegenerative model
[24].
Having successfully shown that 20-223 slows tumor
progression in vivo, we followed up with characterization
of the mechanistic basis for the observed anti-CRC effects
in cell-free and cell-bases studies. For these studies,
we used AT7519 and Roscovitine, both CDK inhibitors
previously explored as anti-cancer CDK inhibitors
in clinical trials. AT7519 and 20-223 share the same
core structure, which makes it an optimal compound to
benchmark the potency of 20-223.
We performed a series of studies to gain insight
into the mechanism associated with the anti-tumorigenic
properties elicited by 20-223. The aminopyrazole core
found in CDK inhibitors has proven successful due to
the flat heterocyclic core and a series of hydrogen bond
donors and acceptors. The positioning of nitrogen atoms
in the aminopyrazole core enables them to compete with
ATP. A hydrogen bond donor acceptor donor triad within
the aminopyrazole core targets the hinge region residues
of the kinase and blocks the binding of ATP [45]. Docking
studies suggested that aminopyrazole analogs 20-223 and
AT7519 interact with Glu81 and Cys83 within the hinge
region of CDK5. Profiling 20-223 against a panel of CDKs
revealed that it most potently inhibits CDK2 and CDK5
over other CDKs. Importantly, 20-223 is more potent than
the clinically used 4-aminopyrazole analog AT7519 in
cell-free kinase assays.
Cell-based studies corroborated cell-free kinase
assays as 20-223 effectively disrupted the kinase activity
of CDK2 and CDK5 in CRC cells. In two of the three cell
lines profiles 20-223 was selective for CDK5 over CDK2.
The observed differential sensitivity/selectivity associated
with 20-223 in three different CRC cell lines suggests that
the functional misregulation of CDKs is probably not the
same across the cell lines. The cell free and cell-based
IC50 values were approximately two-orders of magnitude
apart. This loss of potency when going from a cell free to
cell-based activity assay is commonly observed in drug
discovery programs. For example, Palbociclib the recently
approved CDK4/6 inhibitor has single digit nM potency
LQFHOOIUHHDVVD\VDQGKDVDVLQJOHGLJLWȝ0SRWHQF\LQ
cell based assays [46]. One possible explanation for this
observed difference is the emerging view that kinases are
part of larger protein complexes and evaluating selectivity
in cell-free conditions does not always reflect the effects
observed in the cellular context [47].
Since 20-223 showed ~8-fold selectivity for CDK5
over CDK2 in HCT116 cells we evaluated its efficacy
in inhibiting migration of HCT116 cells in a woundhealing scratch assay. 20-223 treated HCT116 cells
showed reduced cell migration when compared to vehicle
treated HCT116 cells. This is consistent with reported
literature that shows that CDK5 plays an important role
in regulating the migration of cells by phosphorylation of
www.impactjournals.com/oncotarget

Ser732 on FAK [27]. Studies with a CDK2 inhibitor also
showed it blocked EMT and subsequent cell migration,
however in that study the effect of the inhibitor on CDK5
was not determined [30].
As CDK2/5 have been known to drive proliferation
of cancer cells, we investigated the effect of 20-223 on cell
growth in a larger panel of CRC cell lines. Among these
CRC cell lines, 20-223 not only proved to be a nanomolar
inhibitor of cell growth across the panel, but it was also
more potent when compared to AT7519 and Roscovitine.
These results suggest that 20-223 is comparable or in
some cases more potent than the benchmarked clinical
aminopyrazole analog AT7519.
Broadly the cause of CRC cell growth inhibition or
tumor growth inhibition could be either due to induction
of apoptosis or due cell growth arrest. A dose and time
dependent study with 20-223 revealed that CRC cells
UHTXLUHGȝ0FRQFHQWUDWLRQVWRLQGXFH3$53FOHDYDJHD
hallmark for the induction of apoptosis. However at high
Q0WRORZȝ0FRQFHQWUDWLRQVRI$7RUZH
observed cell cycle arrest. Together our data shows that
20-223 phenocopies the cell cycle effects of AT7519 in
CRC cell lines. The observed CRC growth inhibition can
be largely attributed to inhibition of proliferation and to a
lesser extent on the induction of apoptosis.
In summary, our study argues for the continued
preclinical development of 20-223 for CRC therapy.
Collectively, our results reveal that 20-223 exhibits anticancer properties in a CRC mouse model. Mechanism
studies indicate that it inhibits CDK2/5 both in vitro and
in CRC cell lines. Migration of CRC cells was inhibited
by 20-223, which targeted CDK5 and as a consequence
inhibited Ser732 phosphorylation a key event in the
migration of cells. 20-223 inhibits proliferation of CRC
cell lines by inducing cell cycle arrest. A recent review
article outlined in detail the contributions of CDK5 to
many types of cancer, supporting its potential as a novel
target for cancer therapy across many tumor types [48].
While we demonstrated 20-223 is not selective for CDK5,
it does indeed inhibit CDK5 in vitro and in vivo. 20-223
had comparable or in several assays better potency than
the clinically used aminopyrazole CDK inhibitor AT7519,
which is a good benchmark for advancing a compound
through development. In order to explore this core for
improved selectivity, structure activity relationship studies
are currently underway in our lab and will be reported in
due course.

MATERIALS AND METHODS
Chemical inhibitors
20-223 was originally designed and synthesized
by Pfizer (CP668863) and resynthesized in our
laboratory (20-223) (Supplementary Figure 6). Chemical
structure was confirmed using proton and carbon NMR
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(Supplementary Figure 7) and HRMS (Supplementary
Figure 8A). The purity of the compound was analyzed
by analytical HPLC (Supplementary Figure 8B). AT7519
(SelleckChem S1524) and Roscovitine (Apex BioTech
#A1723) were used in head-to-head comparison studies
with 20-223. All three inhibitors were dissolved in 100%
DMSO to a final stock concentration of 10mM.

were measured. Tumor volume was measured with
calipers and calculated using the l2îKîʌHTXDWLRQ
The study was concluded when control tumors reached
maximum size according to facility guidelines. Mice were
euthanized and then full body and excised tumor images
were taken using Near-IR enhanced Macro Imaging
System Plus Cooled with the LT-99D2 with the Dual Tool
excitation upgrade. Tumor samples were preserved in
liquid nitrogen prior to western blot analyses (see below
for Western Blot protocol).

CRC cell lines and reagents
Cell lines used in this study are colorectal cancer
(CRC) cell lines. FET, CBS, and GEO cells were cultured
in serum free medium (McCoy’s 5A medium with sodium
bicarbonate, L-serine, asparagine, sodium pyruvate,
0(0 YLWDPLQV JURZWK IDFWRUV ȝJP/ WUDQVIHUULQ
ȝJP/LQVXOLQDQGQJP/(*) DQG[3HQLFLOOLQ
Streptomycin. SW620, DLD1, and HT29 cells were
cultured in DMEM high glucose medium (HyClone
#SH30022.01) supplemented with 10% FBS (Gibco
by Life Technologies #26140-079) and 1x PenicillinStreptomycin (HyClone # SV30010). HCT116 cells were
cultured in RPMI-1640 Medium (HyClone #SH30027.01)
supplemented with 10% FBS and 1x PenicillinStreptomycin. All CRC cell lines were cultured in 5%
CO2 at 37°C. Cell lines were validated by STR profiling at
the University of Nebraska Medical Center Human DNA
Identification Laboratory (Supplementary Figure 9A).
Cell lines exceeding an 80% match with the online ATCC
database were considered valid [49, 50].

The cancer genome atlas (TCGA) analyses
TCGA provisional data was retrieved from
cBioPortal on January 19, 2017. CRC sample type and
mRNA expression (RNA-seq) was downloaded from
UCSC Xena (https://genome-cancer.soe.ucsc.edu/proj/
site/xena/heatmap/). All provisional cancer datasets
were analyzed for CDK5 mutation. The genomic profile
of CDK5 was further analyzed in the CRC (Colorectal
Adenocarcinoma - TCGA Provisional) dataset for putative
somatic copy-number alterations from GISTIC, using
Onco Query Language (OQL), and mRNA expression
(RNA-seq). GISTIC predicts copy number alterations
according to sample specific thresholds generated
by comparing chromosomal segments with median
chromosomal arm copy numbers. All parameters were set
at default.

Cell-free system analyses
Human colon epithelial cell line

Kinase profiling with 20-223 was carried out with
a panel of CDKs (CDK1, CDK2, CDK4, CDK5, CDK6,
&'.DQG&'. DWDVLQJOHGRVH ȝ0 ZLWKȝ0
ATP in duplicates. The enzymatic activity was determined
for each of the CDKs and follow-up dose response studies
were carried out with CDK2 and CDK5. A 10-point dose
UHVSRQVH VWDUWLQJ DW  ȝ0 RI  RU $7 ZLWK
3-fold dilution was carried out. IC50 values were generated
through fitting the dose response curves.

Immortalized non-transformed human colonic
epithelial cell lines (HCEC) were a gift from J. Shay
(UT Southwestern)[51]. HCECs were grown in medium
composed of 4 parts DMEM to 1 part media 199 (SigmaAldrich) with 2% cosmic calf serum (GE Healthcare), 25
QJP/(*)ȝJP/K\GURFRUWLVRQHȝJP/LQVXOLQ
ȝJP/WUDQVIHUULQQ0VRGLXPVHOHQLWHDQGȝJ
mL gentamycin sulfate. HCECs were grown in a hypoxia
chamber with 2% O2 and 5% CO2 at 37°C.

Western blot analyses
Xenograft studies

Cells were lysed using a buffer containing
50mM Tris, 100mM NaCl, 1% NP-40, 2mM EDTA,
20%SDS combined with 20xPPI (Na3VO4, NAF,
ȕJO\FHURSKRVSKDWH DQGPPRO/306)6DPSOHVZHUH
kept on ice and vortexed prior to centrifugation at 4°C.
Supernatant was collected and protein was quantified
XVLQJ %&$ 3URWHLQ $VVD\ 3LHUFH    ȝJ RI
protein were run on 4-15% gradient gels (BioRad) in
1x TRIS-Glycine SDS (Research Products International
Corporation #T32080) at 120V for ~90 minutes and
separated by SDS-PAGE electrophoresis prior to being
transferred to a PVDF membrane using a Semi-dry
transfer (ThermoScienctific, #35035) at 18V for 35
minutes. The membrane was blocked in 5% milk in 1X

All animal studies were carried out following
approval of the Institutional Animal Care and Use
Committee. This xenograft study has been used previously
in our lab [27]. Briefly, GEO-GFP cells (7x106) were
subcutaneously injected into the flank of athymic nude
mice. Xenograft tumors were allowed to grow until
reaching a volume of 100-200mm3 at which point they
were separated into two treatment groups: DMSO
vehicle control or 8mg/kg 20-223. Each group contained
7 animals (n=7). Drug or vehicle injections were given
subcutaneously daily for the first week and every other
day for two more weeks for a total of 14 injections.
Throughout the study, animal weight and tumor volume
www.impactjournals.com/oncotarget
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Tris Buffered Saline with 0.1%Tween (1xTBST) for 1
hour at room temperature while gently rocking. Primary
antibodies (Supplementary Figure 9B) were incubated
in 5% milk in 1x TBST and rocked overnight at 4°C.
Appropriate HRP-conjugated secondary antibodies were
incubated in 5% milk in 1xTBST and rocked for 1 hour at
room temperature. Protein expression was detected using
ECL Prime (GE Healthcare #RPN2236). Kinase activity
was measured by changes in substrate phosphorylation.
Quantification of phosphorylation levels representative
of the western blots shown were generated using ImageJ.
Blots were performed in triplicate (n=3).

for 1 minute at 4°C and ethanol was removed. Pellets were
washed 1x with 1mL of 1xPBS then centrifuged. PBS was
removed and samples were resuspended in 1mL of Telford
5HDJHQW X0 ('7$ ȝJP/ 51$VH$ ȝJP/
Propidium Iodide, 0.1% Triton X-100, made in 1xPBS)
and incubated at 4°C for 1 hr. Cells were analyzed for
DNA content by flow cytometry. % of cells in the G1, G2,
and S phases were determined for each treatment. (n=2).

Statistical analyses
Graphs and figures were generated using SigmaPlot
11.0 and Graphpad Prism statistical software (GraphPad
Software, Inc). Student’s t-test was used to compare
differences between means between two groups. Oneway analyses of variance (ANOVA) with a post-test for
linear trends was used to compare two or more groups.
For all analyses, significance was inferred at P < 0.05 and
P values were two-sided.

Wound healing migration
HCT116 cells were plated at 1.25x106 cells in 2mL
medium in a 6-well plate and allowed to adhere overnight
and reach 90% confluency. Cells were scratched using a
VWHULOH ȝ/ SLSHWWH WLS GRZQ WKH PLGGOH RI WKH ZHOO WR
create a “wound”. Scratched cells were washed gently with
PBS before being stimulated with a final concentration
of 100ng/mL of EGF (Invitrogen # PHG0311L) and
LPPHGLDWHO\WUHDWHGZLWKHLWKHUȝ0RU'062
control. Directly after the start of treatment, cells were
taken to the live cell imaging facility where they were
imaged every 15 minutes over a 36 hour time course (only
the first 24 hours were considered for migration purposes).
Migration assays were performed in triplicate (n=3).
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